Table 3.

Comparison of ¹¹ In-ibritumomab tiuxetan accumulation and intratumoral distribution between responders and non-responders

	Responder ( n  = 26)	Non-responder ( n  = 16)	p value
SUVmax	2.74 ± 1.43	3.29 ± 1.47	n. s.
% ID/g	0.0022 ± 0.0009	0.0024 ± 0.0008	n. s.
Skewness	0.58 ± 0.16	0.73 ± 0.24	<0.05
Kurtosis	2.39 ± 0.32	2.78 ± 0.53	<0.02
AUC-CSH	0.37 ± 0.04	0.34 ± 0.05	<0.05

n. s., not significant.